January 7, 2013
by admin
4 Comments
The pharmaceutical industry achieved 39 approvals in 2012 – the highest number for several years – triggering a much-needed wave of optimism. But sadly approval is not a guarantee of either patient benefit or commercial success. So DrugBaron looked a … Continue reading
October 29, 2012
by admin
1 Comment
Until 18th October, bardoxolone methyl (Abbott/Reata) and BG-12 (Biogen) had two things in common: the nrf2 transcription factor complex as their molecular target; and their candidacy for blockbuster status. Then Reata halted clinical development of bardoxolone, following an excess of … Continue reading
August 8, 2012
by admin
12 Comments
This week, Pfizer and J&J finally discontinued development of iv bapineuzumab for Alzheimer’s Disease (AD) after a second spectacular failure in Phase 3. That they discontinued the programme surprised almost no-one. Everyone, it seems, is smart after the event, but … Continue reading